Replacement - Director dealing

RNS Number : 5306X
Port Erin Biopharma Investments Ltd
08 February 2013
 



Port Erin Biopharma Investments Limited

 

Replacement - Director's Dealing

 

 

The following amendment has been made to the 'Director's Dealing' announcement released on 30 January 2013 at 9:55am under RNS No 6844W.

Jim Mellon has a beneficial interest in 5,016,000 Ordinary Shares representing 15.2% of the issued ordinary share capital of the Company, not 4,175,000 Ordinary Shares as the previous announcement stated.

 

All other details remain unchanged.

The full amended text is shown below.

 

 

Port Erin Biopharma Investments Limited

 

 ("Port Erin" or the "Company")

 

Director's Dealing

 

 

Port Erin, the AIM listed company focused on investing in the biotechnology and biopharmaceutical sectors, was informed that the Chairman, Jim Mellon, purchased 575,000 Ordinary Shares at an average price of 6.26 pence per share on 29th January 2013.

 

 

Following this transaction, the total Ordinary Shares in which Jim Mellon has a beneficial interest is 5,016,000 representing 15.2% of the issued ordinary share capital of the Company.

 

 

Enquiries:

 



 

Port Erin Biopharma Investments Limited

 

Denham Eke

(+44) 1624 639396

 

 

Libertas Capital Corporate Finance Limited

 

Sandy Jamieson

(+44) 20 7569 9650

 

 

Rivington Street Corporate Finance Limited

 

John Levinson

(+44) 20 7562 3350

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSEAKAPEFADEFF
UK 100

Latest directors dealings